ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years
Weijin Sheng
Matched on OpenAlex author ID A5084227105. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper
Papers 6
- Chemical coupling of an active/passive dual-targeting fusion protein ER(Fv)-HSA to DM1 improves its tumor-specificity and therapeutic efficacy against pancreat… Co-author DOI 10.1016/j.ejps.2025.107188↗
- The recombinant defensin/HSA fusion protein that inhibits NF-κb associated with intensive macropinocytosis shows potent efficacy against pancreatic cancer. Co-author DOI 10.1016/j.bcp.2022.115057↗
- An albumin‑binding domain and targeting peptide‑based recombinant protein and its enediyne‑integrated analogue exhibit directional delivery and potent inhibito… Co-author DOI 10.3892/or.2020.7468↗
- The ionophore antibiotic gramicidin A inhibits pancreatic cancer stem cells associated with CD47 down-regulation. Co-author DOI 10.1186/s12935-019-0862-6↗
- A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer. First author DOI 10.1021/acs.molpharmaceut.8b00234↗
- A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer. Co-author DOI 10.18632/oncotarget.11170↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yong‐Su Zhen · 6 shared papers, 2016–2025 · strength 0.84
- Paper Chemical coupling of an active/passive dual-targeting fusion protein ER(Fv)-HSA to DM1 improves its tumor-specificity a… DOI 10.1016/j.ejps.2025.107188↗
- Paper The recombinant defensin/HSA fusion protein that inhibits NF-κb associated with intensive macropinocytosis shows potent… DOI 10.1016/j.bcp.2022.115057↗
- Paper An albumin‑binding domain and targeting peptide‑based recombinant protein and its enediyne‑integrated analogue exhibit … DOI 10.3892/or.2020.7468↗
- Ying Wang · 1 shared paper, 2025 · strength 0.28
- Xiaofei Wang · 2 shared papers, 2018–2022 · strength 0.25
- Paper The recombinant defensin/HSA fusion protein that inhibits NF-κb associated with intensive macropinocytosis shows potent… DOI 10.1016/j.bcp.2022.115057↗
- Paper A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Panc… DOI 10.1021/acs.molpharmaceut.8b00234↗
- Qingfang Miao · 2 shared papers, 2016–2022 · strength 0.23
- Paper The recombinant defensin/HSA fusion protein that inhibits NF-κb associated with intensive macropinocytosis shows potent… DOI 10.1016/j.bcp.2022.115057↗
- Paper A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy a… DOI 10.18632/oncotarget.11170↗
- Yibo Du · 1 shared paper, 2022 · strength 0.16
- Liang Li · 1 shared paper, 2020 · strength 0.13
- Ruiqi L. Wang · 1 shared paper, 2019 · strength 0.11
- Shuzhen Chen · 1 shared paper, 2018 · strength 0.08
- Yue Du · 1 shared paper, 2016 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.